Significance: Non-invasive optical measures for evaluating rheumatoid arthritis (RA) remain limited. Clinical scores such as the 28-joint Disease Activity Score (DAS28) and ultrasound are operator-dependent and do not directly quantify optical tissue changes. Short-wave infrared (SWIR) hyperspectral imaging (HSI) provides sensitivity to inflammation-associated spectral changes in biological tissues. Aim: The aim is to develop and evaluate a quantitative HSI soft abundance scoring (HSISAS) method for assessing treatment response in RA patients using SWIR-HSI. Approach: Eleven RA patients who met the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria underwent SWIR-HSI (900 to 1700 nm) of the wrist joints before and after 12 weeks of biologic therapy. The HSISAS algorithm used pixel-wise reflectance spectra together with spectral correlation structure estimation and constrained energy minimization-based abundance scoring to compute intra- and inter-subject scores. These scores were statistically compared with conventional clinical indices, including DAS28, erythrocyte sedimentation rate, C-reactive protein, and power Doppler ultrasound findings. Results: ) and were positively associated with DAS28 improvement. Reflectance spectra showed visible pre/post-treatment differences, particularly near 1250 nm. The abundance maps visually differentiated pre- and post-treatment states consistent with clinical improvement. Conclusions: The HSISAS framework provides a quantitative, non-contact optical measure of treatment-related spectral changes in RA. This method may offer translational potential for disease monitoring and may complement existing ultrasound and laboratory assessments.
Chen et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: